Marshall Wace LLP Purchases New Holdings in CeriBell (NASDAQ:CBLL)

Marshall Wace LLP acquired a new stake in CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 31,215 shares of the company's stock, valued at approximately $808,000. Marshall Wace LLP owned about 0.09% of CeriBell at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Legal & General Group Plc purchased a new position in shares of CeriBell during the 4th quarter worth $32,000. Summit Investment Advisors Inc. purchased a new position in CeriBell during the fourth quarter worth about $33,000. PNC Financial Services Group Inc. acquired a new stake in CeriBell in the 4th quarter worth about $47,000. Corebridge Financial Inc. purchased a new stake in CeriBell in the 4th quarter valued at about $158,000. Finally, Wells Fargo & Company MN acquired a new position in shares of CeriBell during the 4th quarter valued at about $167,000.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. LADENBURG THALM/SH SH assumed coverage on shares of CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 target price for the company. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $32.50.

CeriBell Stock Up 0.2 %

CBLL stock traded up $0.04 during midday trading on Friday, reaching $16.32. 208,040 shares of the company's stock traded hands, compared to its average volume of 270,817. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The stock's 50-day simple moving average is $18.85.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. On average, equities analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Activity

In other CeriBell news, CEO Xingjuan Chao sold 15,628 shares of the company's stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $15.11, for a total value of $236,139.08. Following the completion of the transaction, the chief executive officer now owns 727,151 shares in the company, valued at $10,987,251.61. This represents a 2.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 24,700 shares of company stock worth $372,434.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.